The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EORTC CLTF 2018 | Checkpoint inhibitors for cutaneous lymphoma: the way of the future?
Could checkpoint inhibitors be the future of cutaneous T-cell lymphoma (CTCL) therapy? This exciting prospect is explored here by Christiane Querfeld, MD, PhD, from City of Hope, Duarte, CA, at the European Organisation for the Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force (CLTF) 2018 Congress, held in St. Gallen, Switzerland. Dr Querfeld discusses the potential of checkpoint inhibitors for CTCL, and highlights the areas of further study required to optimize our utilization of these agents.
